Welcome to qilu pharmaceutical Co., LTD. -

Located in Jinan City, Shandong Province, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China.  Qilu focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients(APIs) in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Anti-infections, Psychological & Neurological Systems, Respiratory System, Ophthalmological Diseases and several others. Qilu has more than 11000 employees, 70% of which have the college degree or above.
Qilu Pharmaceutical has always maintained an innovative development strategy guided by the market demand and  product innovation. Qilu has established extensive cooperation with domestic and international partners on multiple R&D projects. Qilu pays high attention to the introduction and cultivation of talents, and has built a highly qualified R&D team and efficient R&D capabilities. More than 100 national new drugs have been successfully developed which constitutes a large part of future production and sales for Qilu Pharmaceutical and partners.. A number of technological achievements have garnered national and provincial scientific and  technological progress awards, creating good social benefits.

Qilu Pharmaceutical currently has nine manufacturing sites for finished dosage forms, chemical synthesis, genetic-engineering, fermentation and other production.. The modern production sites incorporate automated production lines utilizing key equipment and analytical instruments from the leading suppliers all over the world. Due to the modern and automated production Qilu has been one of the leading global suppliers of antibiotic and oncology products utilizing and substantial amount of capacity with the highest standard of quality.

Qilu Pharmaceutical has always committed itself to providing high-quality products to patients and the society. Thanks to the integrated and stringent system of quality control and quality assurance, the company has been the leader of cGMP implementation in China. Its comprehensive finished dosages, sterile APIs and non-sterile APIs (fermentation and chemical synthesis) have been respectively approved by USFDA, European Medicines Agency (EMA), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, PMDA of Japan ,, and  other national regulatory authorities.
Qilu Pharmaceutical has an integrated product portfolio and value chain with over 200 launched products. The company has established a comprehensive domestic and overseas sales network, which covers North and South Americas, Europe, Asia, Australia, New Zealand, CIS (Commonwealth of Independent States) countries, South Africa and the Middle East. The valuable brand of the company has been well established with the quality products and good services.